Tagged With glucose

2

Since launching in 2011, Silicon Valley healthcare startup Sano Intelligence has kept a low profile. Despite raising $US20 million ($26 million) in venture capital, the company founded by ex-Bain Capital analyst and bioengineering grad Ashwin Pushpala has yet to release its product — a continuous glucose tracker that sticks to a users' skin and monitors blood through an app. Gizmodo has obtained new details about the device, and how the company intends to market it as a product for "metabolic insight" for non-diabetics, rather than to diabetics who regularly need to track their glucose. The strategy means Sano doesn't need FDA approval in the US, but doctors and diabetes experts interviewed by Gizmodo question whether the product would have any benefits to non-diabetics at all.